Abstract
A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMκ-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20+ cells using rituximab followed by autologous peripheral blood stem cell transplantation. Four years after complete hematological remission he showed marked reduction in size of the amyloid-laden lymph nodes. Deposits of AL amyloid may regress from the tissue if the chemotherapy succeeds in persistent inhibition of the production of an amyloidogenic immunoglobulin light chain.
Abbreviations | ||
VAD | = | vincristine, doxorubicin and dexamethasone |
HDM | = | high-dose melphalan |
SCT | = | autologous stem cell transplantation |
CT | = | computed tomography |
FLCs | = | free light chains |
AL | = | amyloid derived from light chains |
Abbreviations | ||
VAD | = | vincristine, doxorubicin and dexamethasone |
HDM | = | high-dose melphalan |
SCT | = | autologous stem cell transplantation |
CT | = | computed tomography |
FLCs | = | free light chains |
AL | = | amyloid derived from light chains |
Acknowledgements
This work was supported by a grant from the Intractable Disease Division, the Ministry of Health and Welfare, Amyloidosis Research Committee in Japan.